stockportfolio.pro
Castle Biosciences, Inc. (CSTL)
Healthcare · Diagnostics & Research · NasdaqGM
Castle Biosciences, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.79M | $51.87M | $62.65M | $94.08M | $137.04M | $219.79M | $332.07M | $344.23M |
| Gross profit | $17.49M | $44.55M | $52.96M | $78.26M | $105.03M | $174.81M | $271.86M | $273.20M |
| Net income | $-6.37M | $5.28M | $-10.28M | $-31.29M | $-67.14M | $-57.47M | $18.25M | $-24.16M |
| Net margin | -27.9% | 10.2% | -16.4% | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% |
Source: Castle Biosciences, Inc. SEC filings (10-K).
What growth is priced into CSTL stock?
At today's market cap of $635.41M, Castle Biosciences, Inc. is priced for free-cash-flow growth of about 9.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $28.33M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 40.8%/yr over the last five fiscal years and revenue 40.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 8 years of Castle Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CSTL in your portfolio →
Castle Biosciences, Inc. financial history by metric
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences, Inc. — frequently asked questions
What is Castle Biosciences, Inc.'s revenue?
Castle Biosciences, Inc. (CSTL) reported revenue of $344.23M for fiscal year 2025, up 3.7% from the prior year, according to its SEC filings.
Is Castle Biosciences, Inc. profitable?
No — CSTL reported a net loss of $-24.16M in fiscal 2025.
What is CSTL's P/E ratio?
Castle Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Castle Biosciences, Inc. growing?
CSTL's revenue grew at roughly 40.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Castle Biosciences, Inc. have?
As of fiscal year 2025, CSTL carried roughly $10.06M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Castle Biosciences, Inc.'s gross margin?
CSTL's gross margin was 79.4% in fiscal 2025 — gross profit of $273.20M on revenue of $344.23M.
What is Castle Biosciences, Inc.'s market cap?
Castle Biosciences, Inc. (CSTL) has a market capitalization of about $635.41M, based on the latest data in our nightly-refreshed cache.
When does Castle Biosciences, Inc.'s fiscal year end?
CSTL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into CSTL stock?
At today's market cap of $635.41M, Castle Biosciences, Inc. is priced for free-cash-flow growth of about 9.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $28.33M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 40.8%/yr over the last five fiscal years and revenue 40.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Castle Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.